B. Symonds

1422 POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/− RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3

Mark Sulkowski, David Gardiner, E. Läwitz et al. · Journal of Hepatology · 2012 · 80 citations

Medicine, Pharmacology, Pharmacotherapy +16

RG7128 Alone or in Combination with Pegylated Interferon‐α2a and Ribavirin Prevents Hepatitis C Virus (HCV) Replication and Selection of Resistant Variants in HCV‐Infected Patients

Sophie Le Pogam, A. Seshaadri, Aren Ewing et al. · The Journal of Infectious Diseases · 2010 · 60 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1–Infected Individuals: SWIFT-C

Susanna Naggie, Kristen Marks, Michael D. Hughes et al. · Clinical Infectious Diseases · 2017 · 49 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

A phase 2a study evaluating the multi-dose activity of ARB-1467 in HBeAg positive and negative virally suppressed subjects with hepatitis B

Adrian Streinu‐Cercel, Edward Gane, W. Cheng et al. · Journal of Hepatology · 2017 · 34 citations

Medicine, Infectious Diseases, Pharmacology +9